Literature DB >> 34177382

Feasibility and Treatment Effect of a Web-Based Cognitive Behavioral Therapy for Insomnia Program in Individuals with Multiple Sclerosis: A Pilot Randomized Controlled Trial.

Catherine F Siengsukon, Eber Silveira Beck, Michelle Drerup.   

Abstract

BACKGROUND: At least 40% of individuals with multiple sclerosis (MS) experience chronic insomnia. Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for insomnia symptoms in individuals with MS. Delivery of CBT-I using Web-based applications has been shown to be effective and may increase access to CBT-I for individuals with MS who have mobility difficulties, experience fatigue, or live in rural areas. Therefore, the purpose of this study was to assess the feasibility and treatment effect of CBT-I delivered using a Web-based application with or without biweekly telephone calls to improve sleep quality and fatigue in individuals with MS and symptoms of insomnia.
METHODS: Forty-one individuals with MS and symptoms of insomnia were randomized into either a group that participated in a 6-week Web-based CBT-I program (wCBT-I) or a group that participated in a 6-week Web-based CBT-I program and received biweekly support telephone calls (wCBT-I + calls). Participants completed surveys online to assess insomnia severity, sleep quality, fatigue, sleep self-efficacy, depression, anxiety, and motivation to change their sleep behavior.
RESULTS: The overall retention rate was 48.8%, and the adherence rate was 96.34%. Both groups had significant improvement in insomnia severity, sleep quality, sleep self-efficacy, and anxiety. Only the wCBT-I group had significant improvement in depression and fatigue.
CONCLUSIONS: Web-delivered CBT-I is feasible and effective in improving sleep outcomes and concomitant symptoms in individuals with MS. Web-based CBT-I may increase access to CBT-I treatment and provide a stepped-care approach to treating chronic insomnia in individuals with MS.
© 2021 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  Cognitive behavioral therapy; Fatigue; Insomnia; Multiple sclerosis (MS); Web-based

Year:  2020        PMID: 34177382      PMCID: PMC8218587          DOI: 10.7224/1537-2073.2019-122

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  37 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  A randomized controlled trial of an internet intervention for adults with insomnia: effects on comorbid psychological and fatigue symptoms.

Authors:  Frances P Thorndike; Lee M Ritterband; Linda A Gonder-Frederick; Holly R Lord; Karen S Ingersoll; Charles M Morin
Journal:  J Clin Psychol       Date:  2013-08-28

3.  The underdiagnosis of sleep disorders in patients with multiple sclerosis.

Authors:  Steven D Brass; Chin-Shang Li; Sanford Auerbach
Journal:  J Clin Sleep Med       Date:  2014-09-15       Impact factor: 4.062

4.  Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis.

Authors:  Jade Q Wu; Erica R Appleman; Robert D Salazar; Jason C Ong
Journal:  JAMA Intern Med       Date:  2015-09       Impact factor: 21.873

5.  "Go! to Sleep": A Web-Based Therapy for Insomnia.

Authors:  Adam M Bernstein; Didier Allexandre; James Bena; Jonathan Doyle; Gina Gendy; Lu Wang; Susan Fay; Reena Mehra; Douglas Moul; Nancy Foldvary-Schaefer; Michael F Roizen; Michelle Drerup
Journal:  Telemed J E Health       Date:  2017-01-23       Impact factor: 3.536

Review 6.  Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis.

Authors:  James M Trauer; Mary Y Qian; Joseph S Doyle; Shantha M W Rajaratnam; David Cunnington
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

7.  Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

Authors:  J D Fisk; P G Ritvo; L Ross; D A Haase; T J Marrie; W F Schlech
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

8.  Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial.

Authors:  D Kos; M Duportail; Mb D'hooghe; G Nagels; E Kerckhofs
Journal:  Mult Scler       Date:  2007-07-10       Impact factor: 6.312

Review 9.  Computerised cognitive behavioural therapy for insomnia: a systematic review and meta-analysis.

Authors:  Sammy K Cheng; Janine Dizon
Journal:  Psychother Psychosom       Date:  2012-05-11       Impact factor: 17.659

10.  A Computerized Cognitive behavioral therapy Randomized, Controlled, pilot trial for insomnia in Parkinson Disease (ACCORD-PD).

Authors:  Shnehal Patel; Oluwadamilola Ojo; Gencer Genc; Srivadee Oravivattanakul; Yang Huo; Tanaporn Rasameesoraj; Lu Wang; James Bena; Michelle Drerup; Nancy Foldvary-Schaefer; Anwar Ahmed; Hubert H Fernandez
Journal:  J Clin Mov Disord       Date:  2017-08-21
View more
  3 in total

1.  Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; John D Fisk; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; James J Marriott; Charles N Bernstein
Journal:  Front Neurol       Date:  2022-04-14       Impact factor: 4.086

2.  The Impact of Cognitive Behavioral Therapy for Insomnia on Sleep Log and Actigraphy Outcomes in People with Multiple Sclerosis: A Secondary Analysis.

Authors:  Cierra Williams-Cooke; Leslie LeSuer; Michelle Drerup; Catherine Siengsukon
Journal:  Nat Sci Sleep       Date:  2021-10-12

3.  Telehealth-Delivered Cognitive Behavioral Therapy for Insomnia in Individuals with Multiple Sclerosis: A Pilot Study.

Authors:  David Turkowitch; Rebecca Ludwig; Eryen Nelson; Michelle Drerup; Catherine F Siengsukon
Journal:  Mult Scler Int       Date:  2022-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.